Home > Insider Trading > Filing (0001104659-10-043320)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1356857	Trius Therapeutics Inc	TRSX	Pharmaceutical Preparations (2834)	201320630

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1497523	Kpcb Pbd Associates, Llc	C/O Kleiner Perkins Caufield &Amp; Byers 2750 Sand Hill Road Menlo Park CA 94025		No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2010-08-06	1,055,581	$0.00	1,055,581	No	4	C	Indirect	Shares are held directly by KPCB Pandemic and Bio Defense Fund, LLC
Common Stock	Acquisiton	2010-08-06	6,279	$0.00	1,061,860	No	4	C	Indirect	Shares are held directly by KPCB PBD Founders Fund, LLC
Common Stock	Acquisiton	2010-08-06	498,394	$0.00	1,560,254	No	4	C	Indirect	Shares are held directly by KPCB Pandemic and Bio Defense Fund, LLC
Common Stock	Acquisiton	2010-08-06	2,965	$0.00	1,563,219	No	4	C	Indirect	Shares are held directly by KPCB PBD Founders Fund, LLC
Common Stock	Acquisiton	2010-08-06	823,906	$5.00	2,387,125	No	4	P	Indirect	Shares are held directly by KPCB Pandemic and Bio Defense Fund, LLC
Common Stock	Acquisiton	2010-08-06	4,901	$5.00	2,392,026	No	4	P	Indirect	Shares are held directly by KPCB PBD Founders Fund, LLC

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	Shares are held directly by KPCB Pandemic and Bio Defense Fund, LLC
No	4	C	Indirect	Shares are held directly by KPCB PBD Founders Fund, LLC
No	4	C	Indirect	Shares are held directly by KPCB Pandemic and Bio Defense Fund, LLC
No	4	C	Indirect	Shares are held directly by KPCB PBD Founders Fund, LLC
No	4	P	Indirect	Shares are held directly by KPCB Pandemic and Bio Defense Fund, LLC
No	4	P	Indirect	Shares are held directly by KPCB PBD Founders Fund, LLC

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series B Preferred Stock	Disposition	2010-08-06	9,078,000	$0.00	1,055,581	$0.00
Common Stock	Series B Preferred Stock	Disposition	2010-08-06	54,000	$0.00	6,279	$0.00
Common Stock	8% Convertible Promissory Note	Disposition	2010-08-06	498,394	$0.00	498,394	$0.00
Common Stock	8% Convertible Promissory Note	Disposition	2010-08-06	2,965	$0.00	2,965	$0.00

Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect

Footnotes

Series B Preferred Stock was converted into shares of the Issuers Common Stock upon the consummation on the Issuer's initial Public Offering on an 8.6 for 1 basis.
Principal and accrued interest was converted upon the Issuer's initial public offering into shares of Common Stock at a conversion price of 87.5% of the per share price of the Common Stock sold in the Issuer's initial public offering on August 6, 2010, at $5.00 per share.
The Reporting Person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.